This article is more than 5 years old. Information may no longer be current.

Cenegermin eye drops approved in Europe for neurotrophic keratitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Cenegermin eye drops received marketing authorization from the European Commission for the treatment of neurotrophic keratitis.

This is the first biotechnological treatment available for moderate to severe neurotrophic keratitis, according to a press release from Dompé.

Cenegermin, the primary active ingredient of the drug, is a recombinant version of human nerve growth factor and was developed and prepared through a biotechnological production process, the release said. The drops can help restore the normal healing process of the eye and repair corneal damage for patient with moderate to severe neurotrophic keratitis.

The drops are currently an investigational product in the United States, and the company has started the submission of a registration application to the FDA, according to the release.